Early this week, we announced exciting interim results on our monoclonal antibody program with additional Foundation funding to advance the programs to it’s next phases. These results validate our technologies for new applications beyond vaccines and has increased demand for our platforms.

In 2025, our focus is business development—securing strategic licensing, partnerships, and capital to scale our impact. Over the past months:

• Investor interest in our Series A round has accelerated, with multiple firms recognizing Gemini and Jennerator as transformational technologies.
• We are advancing licensing negotiations with pharmaceutical and biotech partners for vaccines, monoclonal antibodies, and therapeutic applications.
• Third-party validation continues to grow, with additional funding secured from strategic partners.

This month’s newsletter covers:

 Investor & Partner Engagement – Key takeaways from J.P. Morgan and upcoming BD efforts.

 Industry Trends & Conference Strategy – The critical events where Eyam is building momentum and closing deals.

 Monoclonal Antibodies & Gemini – How our platform reduces costs, extends duration, and eliminates cold-chain logistics for antibody therapeutics.

We are entering a pivotal phase where execution, speed, and capital efficiency will define our trajectory. If you’re an investor or potential partner interested in shaping the future of biologics, now is the time to connect.

Looking forward,
Ryan Thomas
CEO, Eyam Health

Update from Dr. Pamela Housh, Senior Director of Business Development

Investor & Partner Engagement

The J.P. Morgan Healthcare Conference was a pivotal event for Eyam Health, driving key discussions with investors, pharmaceutical leaders, and biotech VCs. These conversations reinforced that Eyam’s Gemini and Jennerator platforms are recognized as disruptive technologies capable of:

• Delivering a broad range of therapeutic payloads, including antibodies, gene and cell therapies, and vaccines.
• Overcoming delivery system limitations by eliminating reliance on LNPs, AAVs, and traditional vectors.
• Enabling scalable, cost-effective biologic production.

Several firms expressed strong interest in Eyam’s Series A round, recognizing the strategic advantage of its Gemini and Jennerator technologies.

Additionally, ongoing negotiations with existing partners are progressing toward a licensing agreement, further validating industry confidence in Eyam’s pipeline and business model.

Industry Trends from JPM 2025

Key themes from JPM align directly with Eyam’s technology strategy:

• AI-Driven Therapeutics – Increasing demand for AI-powered drug discovery and development platforms like Jennerator.
• Self-Amplifying RNA & DNA – Growing industry interest in next-generation platforms beyond traditional mRNA vaccines, positioning Eyam’s saDNA technology at the forefront.
• Non-LNP Delivery Systems – Investors and partners are actively seeking alternatives to LNP-based delivery, a key differentiator for Gemini.
• Chronic Disease & Oncology – Expanding interest in monoclonal antibodies and cancer therapeutics aligns with Eyam’s strategic focus.

These insights reinforce Eyam’s direction, highlighting opportunities for deeper engagement in oncology, gene and cell therapies, metabolic disease, infectious and chronic disease partnerships.

Strategic Partnerships: Next Steps

Building on JPM momentum, Eyam is now focused on:

• Finalizing licensing negotiations for its saDNA platform with key pharmaceutical and biotech partners.
• Advancing feasibility studies in oncology, chronic diseases, and gene therapy.
• Expanding discussions with pharmaceutical companies to explore collaborations in animal health and vaccine co-development.

With multiple ongoing discussions, Eyam is positioned to secure long-term partnerships that will drive both innovation and commercial success.

Looking Ahead: Key Conferences in 2025

Life Sciences BC & Novateur Biotech BD & Licensing Masterclass (March 2025, Vancouver, BC)

Represented by: Harbir Toor (CFO) & Dr. Pam Housh (Senior Director, Business Development)

Why It Matters:

• Direct engagement with leading biotech and pharma executives from Novo Nordisk, Pfizer, Novartis, AbbVie, Takeda, and J&J.
• Focus on business development and licensing strategies, positioning Eyam for successful negotiations.

World Vaccine Congress (April 2025, Washington, DC)

Represented by: Dr. Pam Housh

Why It Matters:

• Opportunity to showcase Eyam’s vaccine and therapeutic platforms.
• Participation in monoclonal antibody workshops, strengthening Eyam’s leadership in long-lasting biologics.
• Engagement with stakeholders exploring Gemini and Jennerator for vaccine and therapeutic applications.

BioSafe General Membership Meeting (April 2025, Basel, Switzerland)

Represented by: Dr. Pam Housh

Why It Matters:

• Exclusive BIO members-only event at Roche HQ focused on cell and gene therapy, nucleic acid technologies, and therapeutic de-risking.
• High-value discussions with industry leaders to reinforce Eyam’s role in nucleic acid-based therapies.

BIO International (June 2025, Boston, MA)

Eyam’s Largest Industry Event of the Year

Why It Matters:

• The world’s largest biotech conference, bringing together over 20,000 industry leaders.
• Unparalleled networking opportunities with pharma, biotech, and investors.
• A prime platform to drive global partnerships for Gemini and Jennerator.

Represented by: Business Development

TIDES USA 2025 (June 2025, San Diego, CA)

Represented by: Business Development

Why It Matters:

• Leading event for nucleic acid and peptide therapeutics.
• Direct engagement with experts in RNA, saDNA, and peptide therapeutics.
• Strengthening Eyam’s positioning in gene therapy and novel drug delivery.

These conferences will play a key role in advancing Eyam’s business development objectives, securing strategic partnerships, and expanding investor engagement.

Business Development Goals for 2025

Key Focus Areas:

• Convert ongoing licensing negotiations into strategic agreements for Gemini and Jennerator.
• Strengthen investor engagement and advance Series A fundraising discussions.
• Expand co-development partnerships in oncology, infectious disease, and nucleic acid therapeutics.
• Position Eyam as a market leader by highlighting Gemini’s advantages over traditional delivery systems at global biotech events.

With a strong pipeline of opportunities, Eyam is set to build industry-defining collaborations that will shape the future of biologics.

1. What Are Monoclonal Antibodies?

A Simple Definition

Monoclonal antibodies (mAbs) are lab-made proteins that help the immune system fight disease. They work like the body’s natural antibodies but are designed to target a single, specific threat—such as a virus, bacteria, or harmful cell—rather than many different invaders. To create them, scientists copy a single immune cell, ensuring that every antibody is identical and precisely targets the same spot on its intended target. This makes mAbs highly effective for treating infections, cancers, and other diseases.

How They Work

Monoclonal antibodies function by identifying and binding to disease-causing molecules, effectively neutralizing them or marking them for destruction by the immune system. Some of the key uses for mAbs include:

• Cancer Immunotherapy – mAbs like Herceptin and Keytruda help the immune system attack cancer cells.
• Autoimmune Disease Treatment – mAbs like Humira and Remicade reduce inflammation in diseases like rheumatoid arthritis.
• Infectious Disease Prevention & Treatment – Antibodies like Evusheld help protect high-risk individuals from viral infections like COVID-19, while AbCellera’s Bamlanivimab was developed to treat COVID-19 by targeting the virus and preventing it from spreading in the body.
• HIV Treatment – Monoclonal antibodies such as VRC01 are being developed to block HIV from infecting immune cells, offering a potential new approach to prevention and treatment.

Real-World Impact

Monoclonal antibodies have led to groundbreaking treatments for multiple diseases. Here are some of the most well-known:

Monoclonal antibodies have changed how we treat serious diseases, but there are still major limitations preventing their widespread use.

2. Challenges in Traditional Monoclonal Antibody Therapies

High Manufacturing Costs

• Traditional mAbs are produced in large-scale bioreactors using mammalian cell cultures (CHO cells).
• This process is time-consuming, expensive, and dependent on specialized facilities.
• The result: Expensive therapies, often priced above $50,000 per year per patient.

Short Half-Life & Frequent Dosing

• Many monoclonal antibodies require frequent administration (every 2 to 4 weeks) to maintain their effect.
• This leads to higher costs, lower patient adherence, and logistical burdens.

Delivery & Stability Issues

• Most mAbs are delivered via IV infusion, requiring hospital or clinical visits.
• They need cold storage and precise handling, limiting global distribution.

Because of these limitations, millions of patients lack access to life-saving mAb therapies.

3. Eyam’s Gemini Platform: A New Era for Monoclonal Antibodies

Eyam’s Gemini Platform was developed to overcome delivery system limitations and is now being validated for the delivery of monoclonal antibodies. It works by enabling monoclonal antibodies to be expressed directly inside the body rather than manufactured in an external facility.

What is Gemini?

Gemini is Eyam’s self-amplifying DNA platform, designed to:
 Produce monoclonal antibodies inside the patient’s body.
 Extend the duration of mAb therapies, reducing the need for frequent doses.
 Eliminate cold-chain storage, making delivery more accessible globally.

How Gemini Solves Key mAb Challenges

Breakthrough Impact

• Rapid Deployment: Gemini-enabled mAbs can be developed faster than traditional biologics.
• Scalability: Reduces reliance on complex bioreactors and supply chains.
• Longer-Lasting Protection: Gemini’s self-amplifying DNA ensures months-long expression instead of days.

4. Dr. Terry Pearson: A Pioneer in Monoclonal Antibody Research

A Legacy of Innovation

Dr. Terry Pearson, a renowned immunologist and Eyam Board Member, was instrumental in the early development of monoclonal antibody technology for infectious disease research. Working alongside Nobel Laureates César Milstein and Georges Köhler at Cambridge, he made a seminal contribution to medicine by generating the world’s first commercial monoclonal antibody. This breakthrough laid the foundation for the widespread use of monoclonal antibodies in diagnostics, therapeutics, and numerous scientific applications.

Following this achievement, Dr. Pearson joined the International Laboratory for Research on Animal Diseases in Nairobi, Kenya, where he introduced monoclonal antibody technology to Africa, expanding its impact on global health.

Key Contributions

• Developed some of the earliest monoclonal antibodies for infectious diseases.
• Led pioneering research in immunology, diagnostics, and antibody engineering.
• Influenced the design of modern therapeutic antibodies in cancer and autoimmune diseases.
• Introduced monoclonal antibody technology to Africa, advancing diagnostic and therapeutic applications in developing regions.

Dr. Pearson’s Role at Eyam

As an Eyam Board Member, Dr. Pearson provides strategic guidance on our programs, leveraging his expertise in antibody engineering continues to shape Eyam’s approach to next-generation biologics, reinforcing the company’s leadership in innovative therapeutics.

5. Closing Message & Call to Action

Eyam Health is rapidly advancing the future of monoclonal antibody therapies, with three active partnerships already in place and strong interest from additional biotech and pharmaceutical companies. Gemini’s technology is set to transform antibody therapeutics by enabling longer-lasting expression, reduced dosing frequency, and enhanced accessibility—all without the limitations of traditional delivery systems.

As industry demand for innovative biologics grows, Eyam is positioned to lead the next generation of monoclonal antibody development, targeting oncology, chronic disease, and infectious disease applications.

Call to Action

The future of monoclonal antibody therapies is unfolding now, and Eyam’s Gemini platform is at the forefront of this revolution. There is still time to participate in the Pre-Series A Round before it closes—an opportunity to invest in a disruptive technology that is reshaping the biologics landscape.

Join us in building the future of antibody therapeutics. Reach out today to explore investment and partnership opportunities.